A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age).
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age).
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents.
The study duration will be up to 12 months for all participants.
The study duration will be approximately 12 months for all participants
Inclusion Criteria: - Aged 18 to 25 years or 10 to 17 years on the day of inclusion
Birmingham, Alabama 35216, United States
Tempe, Arizona 85281, United States
Washington D.C., District of Columbia 20016, United States
DeLand, Florida 32720-0834, United States
Albuquerque, New Mexico 87107, United States
North Charleston, South Carolina 29405, United States
Simpsonville, South Carolina 29681, United States